Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Exclusive News Is Abbott's January Pullback a Good Time to Buy? Authored by Thomas Hughes. Originally Published: 1/24/2026. 
Summary - Abbott Laboratories’ January pullback looks driven more by sentiment than fundamentals, putting shares back near a prior accumulation zone.
- Quarterly results showed solid sales growth, improving margins, and faster adjusted earnings growth despite a revenue miss.
- A long dividend-growth track record and potential upside implied by analyst targets underpin the bullish rebound case.
Abbott Laboratories' (NYSE: ABT) January 2026 price pullback has made the stock look attractively valued. The move, driven more by market angst than by company-specific weakness, appears to be a knee-jerk overreaction that has pushed the shares back into a buy zone. 
The zone aligns with market action from 2022–2024, when Abbott was recovering from a post-COVID-19 revenue contraction and institutions were actively accumulating the stock. Abbott Laboratories Growth Accelerates Although some metrics missed expectations in Abbott Laboratories' Q4 results and guidance, the underlying business showed strength. Revenue was $11.46 billion — up 4.5% year over year — margins improved, and adjusted earnings accelerated. Revenue growth lagged consensus by several hundred basis points, but margin improvement helped offset that shortfall: adjusted earnings per share (EPS) rose 12%, slightly above expectations. Segment-level results highlighted the breadth of Abbott's diversified healthcare portfolio. Nutrition and Diagnostics contracted — Nutrition declined nearly 9% — but growth in Established Pharmaceuticals and MedTech more than offset those weaknesses. The Pharmaceuticals segment grew about 9%, driven by generics and emerging markets, while MedTech expanded roughly 12.3% with broad-based strength across subsegments. Margins improved, though they were slightly below some analyst forecasts. Still, a favorable product mix, MedTech strength, reduced COVID-19-related sales and operational gains supported the margin picture. Management expects these improvements to continue, forecasting roughly 10% earnings growth in 2026 that should outpace revenue growth and sustain the company's capital-return plans. Capital returns are central to the investment case. Abbott is a Dividend King, having raised its payout annually for more than 50 years, and it appears positioned to continue doing so. After the pullback the stock yields about 2.5%, and the payout ratio is under 50% of consensus EPS, leaving room for share buybacks — another important tool that helps offset the impact of dilutive share-based compensation. See also: why Abbott is a buy for growth and yield. Analysts Point to Robust Rebound in Abbott Laboratories Stock Some analysts highlighted the revenue miss, but no major rating or price-target cuts were issued the morning of the release. The prevailing view is that this is a fundamentally healthy company that can keep returning capital while reinvesting in growth, and the medium-term growth outlook remains meaningful. The consensus share price target reported by MarketBeat implies upside of as much as 30%, which could push the stock back toward — or beyond — prior highs. Even the low-end targets suggest modest upside from current levels. Key catalysts include the expanding MedTech portfolio, integration of AI across operations and products, margin expansion and strategic acquisitions. The planned acquisition of Exact Sciences is one example of how management is broadening revenue and profit streams while adding to the product pipeline. That said, the pullback has been sharp and could deepen. Institutions accumulated shares throughout 2025 and may act as buyers at discounted prices, which helps the bull case. Early technical support appears near $105–$110, though it is not yet confirmed. The main downside risk is the potential for shares to test the low end of the buy zone, perhaps approaching the mid-$90s or lower before any sustained rebound. Bottom line: For long-term investors who can tolerate near-term volatility, the recent weakness in ABT offers a compelling entry point backed by diversified growth, improving margins and a strong capital-return profile. Keep position sizing and downside targets in mind, and monitor whether the $105–$110 support holds or gives way toward the $95 area.
| 
